Activated clotting times, heparin responses, and antithrombin: Have we been wrong all these years?

Anesthesia and Analgesia

Volumn 111, Issue 4, 2010, Pages 833-835

  Levy, Jerrold H ^a   Sniecinski, Roman M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BIOCHEMICAL MARKER; HEPARIN;

ANALYTICAL EQUIPMENT; ANTICOAGULATION; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY GRAFT OCCLUSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; GRAFT OCCLUSION; HEART ARREST; HEART INFARCTION; HEART SURGERY; HEMOSTASIS; HOSPITAL DISCHARGE; INTENSIVE CARE UNIT; LUNG EMBOLISM; MEASUREMENT; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REOPERATION; STROKE; SURGICAL MORTALITY; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; BLOOD CLOTTING TEST; HUMAN; METABOLISM; NOTE; STANDARD;

ANTITHROMBIN III; BLOOD COAGULATION TESTS; HEPARIN; HUMANS; WHOLE BLOOD COAGULATION TIME;

EID: 77957695786     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181f08a80     Document Type: Editorial

References (25)

1. Galletti PM. Cardiopulmonary bypass: a historical perspective. Artif Organs 1993;17:675-686
2. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-763
3. Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res 2008;123:S29-35
4. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999;91:1122-1151
5. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994;57:1211-1216
6. Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 2004; 18:129-130
7. Zaidan JR, Johnson S, Brynes R, Monroe S, Guffin AV. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986;65:377-380
8. Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg 2008;106:713-718
9. Garvin S. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirement. Anesth Analg 2010;111:849-855
10. Garvin S. Heparin dose response is independent of perioperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010;111:856-861
11. Garvin S. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg 2010;111:862-869
12. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg 1988;67:469-472
13. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000;90:1076-1079
14. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440-444
15. Ranucci M, Isgro G, Cazzaniga A, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002;17:199-204
16. Lobato RL, Despotis GJ, Levy JH, Shore-Lesserson LJ, Carlson MO, Bennett-Guerrero E. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010;139:1665-1666
17. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-262
18. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-526
19. Salmenpera M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology 1991; 75:539-541
20. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-113
21. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002; 96:1095-1102
22. Williams MR, D'Ambra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-877
23. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33:355-360
24. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
25. Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg 2008;107:1633-1638